Jaw osteonecrosis related to bisphosphonate treatment of bone metastasis

Journal of Biological Regulators and Homeostatic Agents

Volumn 24, Issue 2, 2010, Pages 115-121

  Raffaelli, L ^a   Scaramuzzo, L ^a   Rossi Iommetti, P ^a   Graci, C ^a   Maccauro, G ^a   Manicone, P F ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Bisphosphonate; Bone metastasis; Osteonecrosis

Indexed keywords

BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; DEXAMETHASONE; PAMIDRONIC ACID; THALIDOMIDE; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT;

BONE LESION; BONE METASTASIS; BONE SCINTISCANNING; CLINICAL FEATURE; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SUBSTITUTION; ERBIUM YAG LASER; HISTOPATHOLOGY; HUMAN; HYPERCALCEMIA; JAW OSTEONECROSIS; NONHUMAN; PATHOGENESIS; RADIODIAGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SOLID TUMOR; TREATMENT DURATION; BONE NECROSIS; BONE TUMOR; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; EDITORIAL; FEMALE; JAW DISEASE; LUNG TUMOR; MALE; MULTIPLE MYELOMA; PROSTATE TUMOR;

ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; DIPHOSPHONATES; FEMALE; HUMANS; JAW DISEASES; LUNG NEOPLASMS; MALE; MULTIPLE MYELOMA; OSTEONECROSIS; PROSTATIC NEOPLASMS;

EID: 77955909878     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Hewitt C, Farah CS. Bisphosphonate-related osteonecrosis of the jaws: a comprehensive review. J Oral Pahol Med 2007; 36:319-28.
2. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005; 63:1567-75.
3. Lacerna L, Hohneker J. Zoledronic acid for the treatment of bone metastases in patients with breast cancer and other solid tumors. Semin Oncol 2003; 30:150-60.
4. st century? J Oral Maxillofac Surg 2005; 63:682-9.
5. Wang J, Goodger NM, Pogrel MA. Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 2003; 61:1104-7.
6. Lanzarovici TS, Yahalom R, Taicher S, Elad S, Hardan I, Yarom N. Bisphosphonate-related osteonecrosis of the jaws: a single-center study of 101 patients. J Oral Maxillofac Surg 2009; 67:850-55.
7. Van Poznak C, Estilo C. Osteonecrosis of the jaw in cancer patients receiving IV bisphosphonates. Oncology 2006; 102:1053-66.
8. Kyle RA, Yee GC, Somerfield MR, et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 2007; 25:2464-72.
9. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 update. J Oral Maxillofac Surg 2009; 67(5): 2-12.
10. Fehm T, Beck V, Banys M , Lipp HP, Hairass M, Reinert S, Solomayer EF, Wallwiener D, Krimmel M. Bisphosphonate-induced osteonecosis of the jaw (ONJ): Incidence and risk factors in patients with breast cancer and gynecological malignancies. Gynecologic Oncology 2009; 112:605-9.
11. Estilo CL, Van Poznak CH, Williams T, et al. Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy. The Oncologist 2008; 13:911-20.
12. Assael LA. Oral bisphosphonate as a cause : of bisphosphonate-related osteonecrosis of the jaws: clinical findings, assessment of risks, and preventive strategies. J Oral Maxillofac Surg 2009; 67(5):35-43.
13. Morag Y, Morag-Hezroni M, Jamadar DA, Ward BB, Jacobson JA, Zwetchkenbaum SR, Helman J. Bisphosphonate-related osteonecrosis of the jaw: a pictorial review. RadioGraphics 2009; 29:1971-86.
14. O'Ryan FS, Khoury S, Liao W, Han MM, Hui RL, Baer D, Martin D, Liberty D, Lo JC. Intravenous bisphonate-related osteonecrosis of the jaw: bone scintigraphy as an earlier indicator. J Oral Maxillo Fac Surg 2009; 67:1363-72.
15. Saussez S, Javadian R, Hupin C, Magremanne M, Chantrain G, Loeb I, Decaestecker C. Bisphosphonate-related osteonecrosis of the jaw and its associated risk factors: a Belgian case series. Laryngoscope 2009; 119:323-9.
16. American Association of Oral and Maxillofacial Surgeons position paper on bisposphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007; 65:369-76.
17. Khamaisi M, Regev E, Yarom N, Avni B, Leitersdorf E, Raz I, Elad S. Possible association between diabetes and bisphosphonate-related jaw osteonecrosis. J Clin Endocrinol Metab 2007; 92:1172-5.
18. Szeto CC, Chow KM. Nephrotoxicity related to new therapeutic compounds. Ren Fail 2005; 27:329-33.
19. Marx RE. Pamidronate (Aredia) and Zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxilofac Surg 2003; 61: 1115-18.
20. Parfett AM. Osteonal and hemiosteonal remodelling. The spatial and temporal framework for signal traffic in adult human bone. J Cellular Biochem 1994; 55: 273-86.
21. Fleish H. Bisphosphonates in bone disease: from the Laboratory to the Patient. San Diego, CA, Academic Press 2000; p. 34-55.
22. Woo SB, Hellstein JW, Kalmar JR. Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006; 144:753-61.
23. Aragon-Ching JB, Ning Y, Chen CC, et al. Higher incidence of osteonecrosis of the jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with antiangiogenic agents. Cancer Invest 2009; 27:221-6.
24. Scavelli C, Di Pietro G, Cirulli T, et al. Zoledronic acid affects over-angiogenic phenotype of endothelial cells in patients with multiple myeloma. Mol Cancer Ther 2007; 6:3256-62.
25. Scheper MA, Badros A, Chaisuparat R, Cullen KJ, Meiller TF. Effect of zoledronic acid on oral fibroblasts and ephitelial cells: a potential mechanism of bisphosphonate-associated osteonecrosis. Br J Haematol 2008; 144:667-76.
26. Reid IR; Bolland MJ, Grey AB. Is bisphosphonate-associated osteonecrosis of the jaw caused by tissue toxicity? Bone 2007; 41:527-36.
27. Allen MR, Burr DB. The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data. J Oral Maxillofac Surg 2009; 67(S):61-70.
28. Sedghizadeh PP, Kumar SK, Gorur A, Shaudinn C, Shukler CF, Costerton JW. Identification of microbial biofilms in osteonecrosis of the jaws secondary to bisphosphonate therapy. J Oral Maxillofac Surg 2008; 66:767-75.
29. Farrugia MC, Summerlin DJ, Krowiak E, Krowiak E, Huntley T, Freeman S, Borrowdale R, Tomich C. Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonates. The Laryngoscope 2006; 116:115-20.
30. Stanton DC, Balasanian E. Outcome of surgical management of bisphosphonate-related osteonecrosis of the jaws: review of 33 surgical cases. J Oral Maxillofac Surg 2009; 67:943-50.
31. Freiberger JJ. Utility of hyperbaric oxygen in the treatment of bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2009; 67:96-106.
32. Vescovi P, Manfredi M, Merigo E, Meleti M, Fornaini C, Rocca JP, Nammour S. Surgical approach with Er: YAG Laser on osteonecrosis of the jaw (ONJ)in patients under bisphosphonate therapy (BPT). Laser Med Sci 2010; 25:101-13.